Cyclophosphamide
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Beijing BiotechSmall moleculePhase 2Active
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 55/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TRASTUZUMAB National Cancer Institute (NCI) | Phase 2 | BB |
PREDNISONE TABLETS National Cancer Institute (NCI) | Phase 2 | B |
Gefetinib National Cancer Institute (NCI) | Phase 2 | B |
DEXAMETHASONE National Cancer Institute (NCI) | Phase 2 | B |
Bortezomib National Cancer Institute (NCI) | Phase 2 | B |
View all 12 →
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →